MOESM2 of Circulating tumor cells capture disease evolution in advanced prostate cancer

Additional file 2. High confidence somatic mutations

Additional file 1: of Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Figure S1. Gating strategy. A Gating strategy for MDSCs; After gating on the single viable cell population MDSCs were identified as the CD3-CD19-CD56-HLA-DR-CD11b + CD33+ cell population. B Gating strategy for circulating tumor cells (CTCs) after EpCAM enrichment CTCs were identified as nucleated, viable CD45-EpCAM+ cells. C Gating strategy for CD1c + mDC1 subset and CD83 expression; viable CD3-CD19-CD56-CD11c + HLA-DR + CD1c + cells were further identified as CD1c + mDC1 and CD83 expression was measured. D Gating strategy for Ki67 + PD-1 + CD8+ T cells and Ki67 + PD-1 + CD4+ T cells. Table S2. Median and IQR of the immunological correlates. Table S3. Percentage of Classic Subsets Expressing PD-L1. PD-L1 clone MIH-1 used to detect surface expression of PD-L1 in immune cell subsets does not compete for binding with durvalumab. These results demonstrate that the PD-L1 clone (MIH-1) does not compete for binding with durvalumab in PBMC and can thus be used to measure PD-L1 expression in patients treated with durvalumab. (ZIP 3994 kb

Additional file 2: of Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

A. Immunophenotyping of myeloid-derived suppressor cells (MDSCs). B. Statistical analysis of pharmacodynamic endpoints. (DOCX 18 kb